Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?
Written by Prosper Junior Bakiny for The Motley Fool -> Pfizer's financial results haven't been great, and upcoming patent cliffs could exacerbate the problem. However, the company's large pipeline
Nasdaq News โ 31 July 2026
Text:
25
0
0
Pfizer's financial results haven't been great, and upcoming patent cliffs could exacerbate the problem.
However, the company's large pipeline across
Read Full Story at Nasdaq News โ Sources
